Latest Spago Nanomedical News & Updates

See the latest news and media coverage for Spago Nanomedical. We track all announcements, press releases, and industry mentions in real time, all in one place.

Spago Nanomedical

Clinical-stage nanomedicine developer for serious disease diagnosis and treatment

spagonanomedical.se

Headquarters: Lund, Sweden
Founded year: 2007
Company type: Public company
Number of employees: 18–50
Industry: Biotechnology & Medical Research

Last updated October 22

Latest news about Spago Nanomedical

In short: Spago Nanomedical proposed First North delisting and raised SEK 15 million in H1 2026 issues

Company announcements

October 22 Spago Nanomedical

Spago Nanomedical proposes delisting from Nasdaq First North Growth Market

The board cites high listing costs and a desire to attract long-term investors for the Tumorad Phase IIa study as key reasons for the move scheduled for late 2026.

October 22 Spago Nanomedical

Spago Nanomedical approves stock option programs and warrant issues

The company resolves directed warrant issuances for employees and board members to secure delivery, causing approximately 2.0% total dilution.

September 21 Spago Nanomedical

Spago Nanomedical announces two employee stock option programs

It convenes an extraordinary general meeting on October 22, 2026, to vote on implementing stock option programs for employees and board members.

June 18 Spago Nanomedical

Spago Nanomedical announces outcome of rights issue

The rights issue was subscribed to 93.1%, raising approximately SEK 15.0 million before costs.

Media coverage

October 22 Dagens industri

Spago Nanomedical applies for delisting from First North

Spago Nanomedical has decided to apply for the delisting of the company's shares from Nasdaq First North Growth Market, subject to a...

August 20 BioSpace

Spago Nanomedical Interim Report January-June 2026 - BioSpace

Spago Nanomedical AB is a Swedish company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique...

June 9 AffärsVärlden

Good backing in Spago's rights issue

Spago Nanomedical has released the information document for its rights issue of SEK 16.2 million. The Emissions Guide raises one positive and two negative flags.

May 22 Dagens industri

Spago raises 16 million - to cover phase 1 study

Spago Nanomedical has decided on a rights issue of approximately 16 million kronor, according to a press release.

Never miss news about Spago Nanomedical

Track Spago Nanomedical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Spago Nanomedical competitors & trending companies

Browse news for competitors to Spago Nanomedical and other trending companies.